Ampio Pharmaceuticals Inc (NYSEAMERICAN:AMPE) reported the appointment of LaVoieHealthScience for their top services in investor and public relations. The latter entity will immediately start designing and implementing a strategic communications plan to expand Ampio Pharmaceuticals’ reach. Its lead candidate named Ampion™ is in an ongoing Phase III clinical study. Ampion marks as a unique biologic and also a low molecular weight ultra-filtrate of HSA, intended for the treatment of symptoms and signs of grave osteoarthritis of the knee.
LaVoieHealthScience is a renowned agency focused on developing science and health innovations. It will be supporting Ampio Pharmaceuticals in their strategic communications with an extensive range of audiences including healthcare professionals, media, the investment community and several others. The agency will use its 16 years of established industry tactics to assist Ampio optimize value and extend visibility.
Michael Macaluso, the CEO and Chairman of Ampio Pharmaceuticals, expressed that as they continue to advance with Ampion, they consider this is the best time to associate with a strategic communications agency and LHS marks as the right choice provided their extensive industry experience. They look forward to associating with the LHS team.
LaVoieHealthScience associates with leading science and health brands to establish value for their firms, attract capital and reach major stakeholders via integrated communications and marketing. The company offers strategic communications, public relations and investor relations to build recognition and enhance value and sales for health science innovations. It has obtained 29 recognitions over the preceding seven years in acknowledgement of the work it has performed for its science and health industry-leading customers, and is listed in the 2017 Inc. 5000 list of rapidly growing private firms for the fourth year.
In the last trading session, the stock price of gained 0.30% to close the day at $1.66. The gains came at a share volume of 658,581 compared to average share volume of 1.30 million.